publication venue for
- A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial. 2024
- On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.. 26:1518-1523. 2024
- Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial.. 26:177-189. 2023
- Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Early Results of the REBALANCE-HF Trial Roll-in Cohort.. 24:1410-1414. 2022
- Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.. 24:169-180. 2021
- Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.. 23:1927-1937. 2021
- Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.. 23:1290-1295. 2021
- Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?. 23:824-825. 2021
- Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.. 23:754-764. 2021
- Pulmonary artery pulsatility index predicts right ventricular myofilament dysfunction in advanced human heart failure.. 23:339-341. 2021
- Towards global improvement in heart failure care.. 22:661-663. 2019
- Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.. 22:148-158. 2019
- Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial.. 21:1476-1479. 2019
- Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial.. 21:693-695. 2019
- Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.. 21:634-642. 2019
- Potential role for interleukin-1 in the cardio-renal syndrome.. 21:385-386. 2019
- Developing evidence-based and accountable health policy in heart failure.. 20:1653-1656. 2018
- Frailty in TOPCAT: a deep dive into the deficit index approach for defining frailty.. 20:1578-1579. 2018
- Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.. 20:1601-1610. 2018
- Prognostic implications of microvascular complications in patients with diabetes and heart failure with reduced ejection fraction.. 20:1557-1558. 2018
- Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.. 20:1436-1443. 2018
- The heart failure readmission quagmire: taking a deep dive to find solutions.. 20:315-316. 2017
- Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.. 20:359-369. 2017
- Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.. 20:715-722. 2017
- A comprehensive population-based characterization of heart failure with mid-range ejection fraction.. 19:1624-1634. 2017
- Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy.. 15:258-66. 2012
- A randomized double-blind crossover trial of triventricular versus biventricular pacing in heart failure.. 14:495-505. 2012
- The relationship between systolic blood pressure on admission and mortality in older patients with heart failure.. 12:148-55. 2010